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Rotavirus is the major cause of severe, dehydrating infantile gastroenteritis. Infection is limited to the gut,
but the relative roles of serum and secretory copro-immunoglobulin A (IgA) in protection are unclear. Specific
copro-IgA is predictive of duodenal antirotaviral IgA and correlates with virus-neutralizing coproantibody.
Copro-IgA conversion is a more sensitive marker of rotavirus reinfection than seroconversion. We measured
rotavirus reinfections by copro-IgA conversion prospectively in 35 children recruited at a time of severe
rotavirus illness. The children were followed up longitudinally for 14 to 31 months to determine whether high
coproantibody levels correlated with clinical protection against rotavirus disease. Ninety-four percent of the
children experienced reinfection, and 38% developed persistent elevations in specific copro-IgA termed
plateaus. Plateau children had a higher mean annual rate of rotavirus infection and a lower ratio of
symptomatic to total number of rotavirus reinfections than did nonplateau children. The annual rates of
rotavirus infection and disease were significantly higher outside the plateau than inside it in children
experiencing antirotavirus copro-IgA plateaus. Frequent rotavirus infection of children appears to stimulate
production of a specific copro-IgA plateau which correlates with protection against an excess of infection and
symptomatic disease.
Rotaviruses are the single most important etiologic agents
of severe diarrheal illness in infants and young children
worldwide (17) and infect the young of most mammalian
species. Rotaviruses are classified into serotypes based on
the reaction of outer capsid proteins VP7 (G types) and VP4
(P types). In neonatal animals, the presence of virus-neutral-
izing antibody in the lumen of the small intestine correlates
with resistance to rotavirus illness (23, 25). Immune protec-
tion in animals is often, but not always, serotype specific (5,
25, 27). Longitudinal studies of children indicate that pri-
mary rotavirus infection results in clinical immunity during
later reinfection (4). The mechanisms responsible for immu-
nity to rotavirus infection and illness in children are not
clear. The presence of specific antibody in serum usually has
not been associated with immunity (2, 8, 17).
In severe, acute rotavirus gastroenteritis in infants and
young children, antibodies in sera and duodenal fluid are
sensitive indicators of rotavirus infection (16). Specific fecal
immunoglobulin A (IgA) shows a high predictive accuracy
for specific duodenal IgA levels at 1 and 4 months postin-
fection (16). Fecal IgA can thus be used as a measure of
intestinal IgA. Changes in antirotaviral copro-IgA correlate
with virus-neutralizing coproantibody conversions and ap-
pear to be more sensitive than seroconversions as measures
of rotavirus reinfections (11). The ability to detect rotavirus
infection by repeated measurement of antirotaviral copro-
IgA presented a nonintrusive means of monitoring rotavirus
infection in young children and of correlating this with
associated clinical symptoms. The aim of the study was to
determine whether coproantibody levels were a correlate of
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clinical protection against rotavirus infection and sympto-
matic disease.
MATERIALS AND METHODS
Patients. We studied 44 children, 3 weeks to 39 months
old, admitted with acute rotavirus diarrhea to the infectious
disease ward between April 1984 and September 1985. The
clinical, demographic, and laboratory findings of these chil-
dren while hospitalized have already been described (16). No
child was breast fed during the study. The study was
approved by the Human Ethics Committees of the Royal
Children's Hospital and the World Health Organization. The
parents of the children gave informed, signed consent. Nine
children did not complete the study, either because they
were withdrawn by their mothers or because the families
relocated and could not be traced. The data presented refer
to the remaining 35 children.
Specimen collection. Acute, convalescent, and 4-monthly
blood samples were collected from each child (11, 16). Fecal
specimens were collected daily while each child was in the
hospital and at 7- to 10-day intervals from all of the children
for at least 14 months and from 20 (57%) of the children for
21 to 31 months. Each family was in telephone contact once
each month with a research nurse, who visited the home 1
week later to obtain specimens and a clinical history of the
child. Parents were asked to contact a pediatrician (K.G.)
immediately if symptoms of enteritis occurred in the child.
The grading system used to assess the severity of clinical
disease was based on that described previously (4). A score
of 0 to 4, describing level and duration, was assigned in each
of three categories: fever, vomiting, and diarrhea. A score of
0 to 3 was assigned to the category of treatment supervision
required: 0, parents alone; 1, infant health nurse; 2, general
practitioner; 3, hospitalization. A total score of 1 to 8
indicated mild disease, and a score of 9 to 14 indicated
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moderate disease. No episodes classifiable as severe were
reported. Extra fecal samples were collected during diar-
rheal episodes. Feces collected by mothers at home were
stored frozen at -4°C for up to 1 month before collection and
transport to the Royal Children's Hospital, where they were
placed at -70°C until tested (16). Feces and sera collected in
the hospital were stored at -70°C until tested.
Specific antibody estimation. Antirotaviral IgA, IgM, and
IgG levels in all of the serum and fecal samples collected
were estimated by enzyme immunoassay (EIA) using SAl
rotavirus as the antigen, as previously described (10). A
seroconversion in IgG or IgA was defined as a fourfold
increase in titer between two consecutive specimens such
that the maximum value was greater than or equal to twice
the positive-negative cutoff (10, 11). A positive IgM response
in serum or feces was defined as a titer equal to or greater
than 1:200. IgA coproconversion was defined as a threefold
increase in EIA units per milliliter, to at least 100 U,
occurring over a period of no more than 3 weeks, with no
more than one coproconversion each month. This definition
of conversions has been validated (10, 11). Rotavirus-neu-
tralizing antibody titers in a subset of 422 fecal samples from
10 children were estimated by fluorescent focus reduction
neutralization of cultivable rotaviruses (11, 12). A significant
elevation in neutralizing antibody, indicating rotavirus infec-
tion, was defined as a fourfold increase in titer to at least
1:400 (11).
Fecal pathogen analysis. All fecal extracts were assayed for
rotaviral antigen by monoclonal antibody EIA with EDTA
treatment (13). Diarrheal feces were also examined for
viruses by electron microscopy after concentration of fecal
extracts. Where possible, the G type of the infecting rotavi-
rus was determined by monoclonal antibody EIA (13). G
type 1 rotaviruses were classified as monotype a, b, or c by
reaction with a panel of monoclonal antibodies as described
previously (9). Feces collected during diarrheal episodes
were also cultured for the presence of salmonellae, shigellae,
Campylobacter jejuni, Yersinia enterocolitica, and entero-
pathogenic Escherichia coli and examined by light micros-
copy for Giardia lamblia cysts.
Statistical methods. Chi-square, t, Mann-Whitney, and
Wilcoxon statistical tests were performed by using the
Minitab statistical software (20). Logit analyses were done
on the Melbourne University VAX computer by using the
GLIM 3.77 system (19, 22). In all analyses, statistical
significance was achieved at the 5% level.
RESULTS
Relationship of rotavirus G type and monotype to severity of
illness at hospitalization and on first reinfection. The G type
and monotype of the rotavirus responsible for the severe,
presumably primary (16), infection which precipitated hos-
pitalization and recruitment to the study were determined in
30 (86%) of the children. During 1984, G type lc predomi-
nated (10 [53%] of 19), with G type 4 common, especially
from July to September (6 [32%] of 19). G type la was found
in two May 1984 recruits (2 [13%] of 19) but predominated in
1985 (8 [89%] of 9). One child in each year was infected by
rotavirus of dual G type: lc and 4 in 1984 and la and 4 in
1985. These are not included in the following analysis. The
infecting G type did not correlate with the severity of disease
during hospitalization, as assessed by the need for intrave-
nous treatment. However, there was a trend for children
recruited in 1984 to be more likely than those recruited in
1985 to have symptoms on their first rotavirus reinfection
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FIG. 1. Incidence of rotavirus infection and disease in children
with and without an antirotaviral copro-IgA plateau. Symbols: ,
follow-up period; - plateau period; El, asymptomatic copro-IgA
conversion; *, symptomatic copro-IgA conversion; R, rotavirus
detected in stools; *, end of first rotavirus season after that in which
the child was hospitalized with severe rotavirus gastroenteritis
(November).
(Fisher's exact test, P = 0.053). Within the 1984 group, there
was also a trend for children infected with G type la or lc
virus to be more likely than those infected with G type 4
virus to be symptomatic on their first rotavirus reinfection
(Fisher's exact test, P = 0.054).
Detection of prolonged elevations in copro-IgA to rotavi-
rus-the coproantibody plateau. Coproconversion following
primary rotavirus infection lasted for up to 75 days before
copro-IgA levels returned to the baseline (16). Copro-IgA
profiles of 12 of the 35 study children showed prolonged
elevations above the copro-IgA baseline that developed after
the initial infection. A prolonged elevation was arbitrarily
termed a copro-IgA plateau. This was defined as an elevation
in copro-IgA to at least 100 U for at least 90% of a period of
not less than 120 days.
Figure 1 represents plateau development in 12 children
contrasted with the 23 children who did not develop a
plateau. Plateaus appeared 2 to 11 months after recruitment
and lasted from 139 to more than 773 days. In all but one
case, the plateau began at the time of the first or second
rotavirus reinfection. One child (no. 35) had two plateau
periods. The geometric mean units of antirotaviral copro-
IgA in each child showing a plateau ranged from 111 to 462
(median, 205) during the plateau period and from 3 to 99
(median, 53) outside the plateau period. The children with-
out a copro-IgA plateau showed geometric mean units of 5 to
84 (median, 23).
Kinetics of responses of plateau and nonplateau children.
One hundred sixteen coproconversions were recorded in 33
of the 35 children, including 62 coproconversions in children
without a copro-IgA plateau and 54 in children before,
during, and after a coproantibody plateau. Rotavirus copro-
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FIG. 2. Antirotaviral copro-IgA and neutralizing antibody profiles of a child with a specific copro-IgA plateau. Symbols: CA to CF,
specific IgA coproconversion; 0, episode of gastroenteritis; *, episode of gastroenteritis with rotavirus in stools. FFN, fluorescent-focus
neutralization.
IgA and neutralizing coproantibody profiles illustrative of
those measured in the children with and without IgA pla-
teaus are shown in Fig. 2 (patient no. 33) and 3 (patient no.
21), respectively. Up to day 720, patient no. 33 experienced
five copro-IgA conversions following the initial low-level
rapid coproconversion (CA) during severe rotavirus infec-
tion at the age of 23 months. The second coproconversion
(CB) was symptomatic and associated with rotavirus-spe-
cific copro-IgM and rotavirus excretion. Three of the later
coproconversions (CB, CE, and CF) were concurrent with
seroconversion in IgA or IgG. Three of the five rotavirus
reinfections were associated with symptoms (CB, CE, and
CF). With the exception of the fourth coproconversion (CD),
all were of large and increasing amplitude. The plateau began
with the second rotavirus reinfection (CC) and persisted at
least to the end of the study, 930 days after recruitment. A
seventh coproconversion at day 740, illustrated in Fig. 1 but
not in Fig. 2, was accompanied by IgG seroconversion.
Nonplateau child no. 21 showed only IgA and IgM class
serum responses to the initial severe rotavirus infection at
the age of 2 months and delayed copro-IgA conversion (CA).
Patient no. 21 experienced only two further IgA coprocon-
versions (CB and CC), which were symptomatic, accompa-
nied by specific copro-IgM or seroconversion, and of in-
creasing amplitude. After each coproconversion, copro-IgA
levels fell to below the positive-negative cutoff (28 U), so
that a plateau was not formed.
In both plateau and nonplateau children, the copro-IgA
profiles were closely paralleled by the neutralizing antibody
profiles, particularly to rotaviruses RV-3 (G3 P2), RV-4 (Gl
PlA), and ST-3 (G4 P2). Antibodies to RV-5 (G2 P1B), Ku
(Gl PlA), and Wa (Gl P1A) appeared at the time of the IgA
coproconversions. It was not possible to determine the virus
serotypes responsible for the reinfections from the neutral-
izing antibody profiles because of these multiple responses.
Rotavirus reinfection and development of disease in relation
to the presence or absence of a copro-IgA plateau. All of the
children were followed up for at least one complete rotavirus
season after recruitment, and 13 (37%) were followed up for
a second complete season (Fig. 1). The data from the first
season and from the combined seasons were considered
separately. Too few children were followed up for a second
season for separate analysis of that group. In the combined
seasons, 22 (41%) of the rotavirus reinfections in plateau
children were associated with symptoms and 34 (55%) of the
reinfections in nonplateau children were symptomatic. In six
(5.2%) of the rotavirus reinfections, symptoms were classi-
fied as moderate. Two of these were in plateau children, and
four were in nonplateau children. In all other symptomatic
reinfections (n = 50), symptoms were classified as mild.
There was no statistically significant difference between the
plateau and nonplateau groups in the severity of the symp-
toms recorded (mild or moderate).
There were no statistically significant differences between
the plateau and nonplateau children for age of recruitment,
sex, severity of rotavirus infection at presentation, or num-
ber of rotavirus seasons followed up (Table 1), although
there was a trend for the rotavirus infection to be more
severe at presentation in the nonplateau group (P = 0.06).
As shown in Table 2, plateau and nonplateau children
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FIG. 3. Antirotaviral copro-IgA and neutralizing antibody profiles of a child without a specific copro-IgA plateau. For definitions of
symbols, see the legend to Fig. 2. FFN, fluorescent-focus neutralization.
were comparable for number of days surveyed. Judged by
IgA coproconversion, children who developed a plateau
showed a significantly greater mean annual rate of rotavirus
infection (2.88) than did nonplateau children (1.83) in the first
season following recruitment (P = 0.008). During the com-
bined seasons also, plateau children were infected with
rotavirus at a significantly greater median annual rate (2.18)
than nonplateau children (1.58; P = 0.030). However, the
mean annual rates of symptomatic rotavirus infection were
not significantly different between the plateau and nonpla-
teau children in the first season (1.01 versus 0.99; P = 0.96)
or the combined season (0.82 versus 0.92; P = 0.78).
In the season following their recruitment, the plateau
children showed symptoms during a mean proportion of 0.33
of their rotavirus infections. This proportion was signifi-
cantly less than that in the corresponding period in nonpla-
teau children (0.60; P = 0.042). The same trend in propor-
tions of symptomatic infection was evident when data for the
second season following recruitment were included, but the
difference was not statistically significant (P = 0.061). The
antibody plateau continued into the second season in only
one of the six plateau children studied (Fig. 1, no. 33).
Among plateau children during the season following their
recruitment, the numbers of days to which each child was
followed up inside and outside the plateau period were
comparable (Table 3). These children showed a significantly
lower median annual rate of infection inside the plateau
period (2.14) than outside it (3.00; P = 0.011). This rate
outside the plateau was also significantly greater than that in
nonplateau children (1.49; Mann-Whitney test, P = 0.001).
Rotavirus infections inside the plateau were significantly less
likely to be symptomatic (0.51 per year) than those outside
the plateau (2.14 per year; P = 0.041). This rate outside the
plateau was not significantly different from the rate in
TABLE 1. Descriptive statistics of plateau and nonplateau children
Mean age (mo) at No. male Intravenous No. followed up for:Group recruitment ml/treatment
(no. of children) (95% C.I.a) no. female Yes No 1 Season 2 Seasons
Plateau (12) 16.9 (11.422.4)b 7/5c 5d 7d 6e 6e
Nonplateau (23) 18.0 (13.9-22.2)" 14/9 17d 6d 16e 7e
a C.I., confidence interval.b P = 0.73 by the t test.
P = 0.9 by the chi-square test.
d P = 0.06 between groups by logit analysis of proportions.
e P = 0.12 between groups by logit analysis of proportions.
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TABLE 2. Comparison of rates of rotavirus infection and symptomatic disease in plateau and nonplateau children
Mean annual rate of symptomatic Mean proportion of rotavirusGroup Mean no. of days followed up Annual rate of rotavirus infection' rotavirus infection"' (95% CI.) infections with symptoms (95%
(no. of (95% C.I.a) during: (95% C.I.) during: during: C.I.) during:
children)
1 Season 2 Seasons 1 Season" 2 Seasons' 1 Season 2 Seasons 1 Season 2 Seasons
Plateau (12) 474 (442-505)d 706 (582-830)e 2.88 (2.23-3.54y 2.18 (1.78-2.53)9 1.01 (0.21-1.80)" 0.82 (0.16-1.48)' 0.33 (0.12-0.54' 0.34 (0.1240.56)k
Nonplateau 490 (472-508)d 630 (554-706)e 1.83 (1.42-2.25f 1.58 (0.88-2.27) 0.99 (0.70-1.28)' 0.92 (0.65-1.19)' 0.60 (0.43-0.78Y 0.58 (0.43-0.74)k(23)
aC.I., confidence interval.
^ Mean values.
Median values.
d p = 0.35 by the t test.
e P = 0.27 by the t test.
fP= 0.008 by the t test.
g P = 0.030 by the Mann-Whitney test.
p= 0.96 by the t test.
P= 0.78 by the t test.
P= 0.042 by the t test.
kp = 0.061 by the t test.
'Mean number of rotavirus infections (number of copro-IgA conversions) each year for each child.
Mean number of symptomatic rotavirus infections (number of copro-IgA conversions associated with gastrointestinal symptoms) each year for each child.
nonplateau children (0.99; t test, P = 0.19). The mean annual
rates of rotavirus infection and symptomatic infection in
plateau children during a plateau (Table 3) were not signifi-
cantly different from those in nonplateau children (Table 2; t
test, P = 0.80 and 0.11, respectively). Thus, during a
plateau, plateau children showed lower annual rates of
infection and symptomatic infection than in the period
outside the plateau. These rates inside the plateau were
comparable to the rates of the children who produced no
antibody plateau at all.
Relationship of age at time of coproconversion to likelihood
of symptomatic illness. Logit modelling of the probability of
symptomatic rotavirus infection for each individual child
showed that there was no significant effect of age on rate of
symptomatic infection (beta = -0.18; standard deviation =
0.12; P > 0.2). Thus, the increasing age of each patient
during the longitudinal study was not associated significantly
with increased resistance to rotavirus disease, although a
trend was evident. The lack of dependence of rate of
symptomatic rotavirus infection on age was the same for
both plateau and nonplateau children (P > 0.15).
Relationship of contact with other children to development
of an antirotaviral copro-IgA plateau. During the study
period, six (17%) of the children attended a day-care center
full time for 1 to 2 years. Half of these children developed an
TABLE 3. Comparison of rotavirus infection and symptomatic
disease in the periods inside and outside the plateau for
children' with antibody plateaus in the first rotavirus
season after their recruitment
Median no. of Annual rate of Mean annual rate
Period days followed rotavirus infectionf of symptomatic
up (95% C.I.6) (95% C.I.) rotavirus infectio)
Inside plateau 272 (211-332)C 2.14 (1.37-2.47)d 0.51 (0-1.04)e
Outside plateau 201 (137-266)c 3.00 (2.50-6.39)d 2.14 (0.33-3.96)e
an = 12.
h C.I., confidence interval.
c P = 0.23 by the t test.
d p = 0.011 by the Wilcoxon test.
e p = 0.041 by the t test.
f Defined in Table 2, footnote 1.
g Defined in Table 2, footnote m.
antibody plateau. There was no significant difference in the
attendance rates at day care between the plateau and non-
plateau groups (Fisher's exact test, P = 0.23). Four plateau
children had younger siblings at home (33%), a rate compa-
rable to that of nonplateau children (13%; Fisher's exact
test, P = 0.13). However, there was a trend for children with
younger siblings or who attended day care full time to be
more likely to develop plateaus (Fisher's exact test, P =
0.054). Among the children recruited in 1984 (9 plateau and
14 nonplateau), this trend reached statistical significance
(Fisher's exact test, P = 0.027).
DISCUSSION
Frequent longitudinal measurement of antirotaviral copro-
IgA levels in 35 children (after an initial severe rotavirus
infection) showed that 33 (94%) experienced rotavirus rein-
fections and that 38% of the children developed persisting
elevations of antirotaviral copro-IgA that lasted for up to 773
days. These persisting elevations have been designated
coproantibody plateaus. Similar persisting elevations of co-
pro-IgA levels were probably also present in five children
studied by Nishio et al. (21). During the plateau, copro-IgA
was associated with persisting rotavirus-neutralizing activ-
ity, mainly directed at the G types of rotavirus responsible
for the initial severe infection. Boosts in neutralizing anti-
body titers to more than one G type were always observed on
reinfection, so that it was not possible to assign a serotype to
the infecting virus by this indirect method. Similar heterotypic
neutralizing antibody responses have been found in sera
obtained during rotavirus reinfection (7, 14).
In this study, symptomatic rotavirus reinfection was
rarely associated with virus shedding detectable by electron
microscopy or EIA. Detection and G typing of rotaviruses
responsible for the reinfections observed are under way
using the polymerase chain reaction technique described by
Gouvea et al. (15). In preliminary testing of fecal samples
from four reinfections in which virus was not detectable by
other methods, G type 1 virus was present in two reinfec-
tions and no rotavirus was detected in two reinfections (18).
This is consistent with our data showing that IgA coprocon-
version in the absence of detectable virus particles or antigen
is a reliable and sensitive measure of rotavirus reinfection
(11). It is possible that the copro-IgA conversions uncon-
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firmed by any other antibody or antigen assay were not
caused by rotavirus infection. However, we believe that the
evidence presented in our previous publications (11, 16)
strongly suggests that the copro-IgA conversions are rotavi-
rus specific.
The observed trend for children recruited in 1984 to be
more likely to show symptoms on their first rotavirus rein-
fection than those recruited in 1985 may be related to the
prevailing rotavirus G types in children admitted to Mel-
bourne hospitals with gastroenteritis from 1984 to 1986. G
types altered from lc (major), 4 (common), and la (minor) in
1984 to la (major), lc (rare), and 4 (rare) in 1985 and to la
only in 1986 (6). Children recruited in 1985 were all infected
with G type la at that time and were likely to be reinfected
with the same G type during 1985 and 1986, whereas those
recruited in 1984 were likely to have been exposed to
different G types during 1984 and 1985. The 1984 recruits
with G type 4 infections also showed a trend to a lower
incidence of symptoms on first reinfection. Further polymer-
ase chain reaction typing of rotavirus from reinfections may
help answer this question.
The children who developed a copro-IgA plateau had
more frequent rotavirus reinfections than children who did
not develop a plateau (P = 0.03). This increased frequency
related to their period of follow-up outside the plateau period
(P = 0.011). It is probable that frequent infection with
rotavirus produced anamnestic gut IgA responses that led to
plateau formation. Intestinal anamnestic responses to rota-
virus have also been recorded elsewhere (28). It is likely that
once a plateau was established, it was sustained by reinfec-
tion, which occurred at a rate lower than that outside the
plateau but similar to that of nonplateau children. The plateau
children, particularly those recruited in 1984, were more
likely to have younger siblings or to attend day care than were
the nonplateau children. It is therefore probable that the
plateau children were exposed to rotavirus more often than
were the nonplateau children, causing the higher frequency of
rotavirus infection observed in the plateau group.
The appearance of a plateau could also be correlated with
resistance to symptomatic infection. Once a plateau devel-
oped, children were less likely to show enteric symptoms
during rotavirus reinfection than in the period without an
antibody plateau. The duration of this protective effect (5 to
26 months) was similar to that observed against severe
disease (at least 18 months) in children asymptomatically
infected with rotavirus as neonates (4) and to that in children
infected at 2 to 12 months of age (at least 2 years) (1). It is
likely that similar mechanisms were involved in the protec-
tion against disease observed in these studies.
This study population was selected on the basis of severe
rotavirus infection. In a birth cohort of randomly selected
Melbourne children being followed longitudinally, rotavirus
infections have been common and copro-IgA plateaus have
occurred in a proportion of children on rotavirus reinfection
(3). This preliminary finding suggests that the selection
criteria did not bias this study towards unusually susceptible
children. It is unlikely that immune antibody enhancement of
infection occurred, as infection was most common in plateau
children during the period when their coproantibody levels
were low.
Our results demonstrate a direct correlation between high
levels of intestinal IgA antibody to rotavirus and a significant
degree of protection of children against natural rotavirus
infection and disease. In stools, the presence of IgA anti-
body to rotavirus has been shown to correlate with the
presence of rotavirus-neutralizing antibody (11, 12). These
results are not in full agreement with data on adults chal-
lenged with human rotavirus CJN, when jejunal neutralizing
antibody levels correlated inversely with the probability of
illness and IgG levels in serum correlated inversely with the
probability of infection (26). These responses may be pecu-
liar to adults (26).
It is likely that immune mechanisms additional to neutral-
ization of virus by antibody contributed to the protection
observed in plateau children. Gastrointestinal cytotoxic T
lymphocytes and intraepithelial lymphocytes are elicited in
mice after oral rotavirus inoculation (24). Stimulation of
specific memory T-cell clones on rotavirus reinfection may
therefore enhance intestinal antibody production. Rotavirus-
infected cells stimulate human leukocytes to produce a
cytokine that enhances natural-killer cell activity (29). These
cells can be mobilized quickly during infection and may play
an important part in limiting acute viral infections (2).
On the basis of this study, we hypothesize that rotavirus
infection of children at sufficiently frequent intervals stimu-
lates production of a specific coproantibody plateau. This
plateau is a correlate of resistance to natural rotavirus
infection and disease in children who have experienced
severe rotavirus gastroenteritis and frequent rotavirus rein-
fection previously. The resistance observed reduces the
infection and disease rate of plateau children to that of
nonplateau children, who have a lower frequency of expo-
sure to rotavirus. Specific copro-IgA is predictive of duode-
nal antirotaviral IgA, and persisting levels of IgA in the small
intestine could protect against infection and symptomatic
disease. Further studies are under way to determine whether
most children in a population produce antirotaviral copro-
IgA plateaus and whether plateaus always result from rein-
fection or also from primary rotavirus infection. It will be
most interesting to examine whether vaccination of children
with rotavirus stimulates IgA coproconversion or plateau
production and, if so, whether these are measures of vaccine
efficacy.
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